1.05%
22.53%
32.81%
20.79%
12.75%
154.59%
148.02%
AI Spotlight on LQDA
Company Description
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension.It also distributes generic treprostinil injection in the United States.
Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Market Data
| Last Price | 14.41 |
| Change Percentage | 1.05% |
| Open | 14.36 |
| Previous Close | 14.26 |
| Market Cap ( Millions) | 1220 |
| Volume | 545740 |
| Year High | 16.99 |
| Year Low | 8.26 |
| M A 50 | 11.69 |
| M A 200 | 11.65 |
Financial Ratios
| FCF Yield | -7.58% |
| Dividend Yield | 0.00% |
| ROE | -155.77% |
| Debt / Equity | 2.43% |
| Net Debt / EBIDTA | 188.24% |
| Price To Book | 10.21 |
| Price Earnings Ratio | -9.45 |
| Price To FCF | -13.19 |
| Price To sales | 78.13 |
| EV / EBITDA | -9.5 |
News
- Jan -22 - Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last?
- Jan -09 - Liquidia named a top pick for 2025 at Needham
- Dec -12 - Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect?
- Nov -26 - Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High?
- Nov -15 - Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off
- Nov -13 - Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript
- Nov -13 - Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
- Nov -13 - Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
- Nov -04 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Nov -02 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Nov -01 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -29 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -29 - Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- Oct -27 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -25 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -23 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -21 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -19 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -18 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
- Oct -16 - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia Corporation - LQDA
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharmaceutical Products
Expected Growth : 9.27 %
What the company do ?
Liquidia Corporation's biopharmaceutical products utilize its proprietary PRINT technology to develop and manufacture precision particles for improved drug delivery and efficacy.
Why we expect these perspectives ?
Liquidia Corporation's biopharmaceutical products exhibit 9.27% growth driven by increasing demand for precision medicine, advancements in nanotechnology, and strategic partnerships. Additionally, the company's proprietary PRINT technology enables targeted drug delivery, expanding its product pipeline and addressing unmet medical needs.
Liquidia Corporation Products
| Product Range | What is it ? |
|---|---|
| Yutrepia | Yutrepia is a treatment for pulmonary arterial hypertension (PAH). It is a novel, inhaled dry powder formulation of treprostinil, a vasodilator that helps to relax the blood vessels in the lungs and improve exercise ability. |
| LIQ865 | LIQ865 is a novel, inhaled dry powder formulation of treprostinil, being developed for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD). |
| LIQ861 | LIQ861 is a novel, inhaled dry powder formulation of treprostinil, being developed for the treatment of pulmonary hypertension associated with sarcoidosis. |
Liquidia Corporation's Porter Forces
Threat Of Substitutes
Liquidia Corporation's products are moderately susceptible to substitutes, as patients may opt for alternative treatments or medications for their conditions.
Bargaining Power Of Customers
Liquidia Corporation's customers, primarily patients and healthcare providers, have limited bargaining power due to the company's specialized products and limited competition.
Bargaining Power Of Suppliers
Liquidia Corporation's suppliers, including contract manufacturers and raw material providers, have moderate bargaining power due to the company's dependence on a few key suppliers.
Threat Of New Entrants
The threat of new entrants in the pharmaceutical industry is low due to high barriers to entry, including significant research and development costs and regulatory hurdles.
Intensity Of Rivalry
The pharmaceutical industry is highly competitive, with many established players and a high level of rivalry among companies, including Liquidia Corporation.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 6.90% |
| Debt Cost | 5.15% |
| Equity Weight | 93.10% |
| Equity Cost | 5.15% |
| WACC | 5.15% |
| Leverage | 7.41% |
Liquidia Corporation : Quality Control
Liquidia Corporation passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CTMX | CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The … |
| AKBA | Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral … |
| MDXG | MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts … |
| URGN | UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation … |
| HRMY | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Harmony Biosciences
A-Score
1-Year Total Return ->
🥈
Akebia Therapeutics
A-Score
1-Year Total Return ->
🥉
MiMedx
A-Score
1-Year Total Return ->
4
CytomX Therapeutics
A-Score
1-Year Total Return ->
5
UroGen Pharma
A-Score
1-Year Total Return ->
6
